Our performance

Working with suppliers

We are committed to integrating AstraZeneca ethical standards into our procurement activities and decisions worldwide.

7,138 supplier risk assessments conducted since the start of the assessment programme in 2009.

2013 Audits by geographic region. 61 audits in total:

  • Asia Pacific: 28
  • Europe: 20
  • Americas: 11
  • Middle East & Africa: 2

0 suppliers removed from supply chain.

53% of suppliers audited demonstrated standards that met our expectations with a further 41% implementing improvements to address minor non compliances.

0% of suppliers audited this year will require significant follow up to confirm they meet our expectations.

24 improvement plans completed.
 

Risk assessments

Since the programme began in 2009, we have completed 7,138 assessments of new and existing suppliers, which accounts for approximately 90% of supplier spend.

Onsite audits

We categorise suppliers as high or low risk. We focus our auditing efforts on high risk rated suppliers but we also audit some suppliers that we consider to be lower risk, to confirm our performance expectations across all suppliers we do business with. In 2013 we continued our audit activity with 61 audits across 25 countries (482 audits in 2012). On year-on-year decrease reflects the finalisation of the retrospective assessment of all our incumbent suppliers. 

Audit findings

53% of suppliers audited demonstrated standards that met our expectations with a further 41% implementing improvements to address minor non compliances. We monitor progress across all corrective actions and 0% of suppliers audited this year will require significant follow up to confirm they will make the improvements we require. We will not use suppliers who are unable or unwilling to meet our expectations in a timely way. Our suppliers are consistently demonstrating high adherence to labour standards and laws, while the most frequently occurring challenges are in the areas of fire detection and protection systems, management and monitoring of second tier suppliers and the introduction of transparent and complete anti-bribery and data privacy controls.

 

Go back to...

Next section

Working with suppliers

Read more

Patient safety

We work continuously to identify and minimise the risks and maximise the benefits of each of our medicines.

Read more

Responsible Business Summary report 2011 front cover

Our Responsible Business Plan provides the framework for managing our sustainable development